Does Pegylated-Interferon Still Have High Efficacy Treatment Properties Against Chronic Hepatitis B?
VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, cilt.24, sa.3, ss.90-95, 2018 (ESCI, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 24 Sayı: 3
- Basım Tarihi: 2018
- Doi Numarası: 10.4274/vhd.2018.0006
- Dergi Adı: VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.90-95
- Kocaeli Üniversitesi Adresli: Evet
Özet
Objectives: Pegylated-interferon (Peg-IFN) alpha 2a/2b and nucleoside and/or nucleotide analogues (NAs) are currently the only two treatment approaches approved for the chronic hepatitis B (CHB). To date, few studies have compared Peg-IFN with NAs in the treatment of CHB. We aimed in this study to evaluate the effectiveness of Peg-IFN and potent NAs (entecavir and tenofovir disoproxil) and to compare cumulative virological and serological resnonses in Turkish CHB patients treated between 2006 and 2016.